Harnessing the Nerve: Vagus Nerve Stimulation for Rheumatoid Arthritis
Article contributed by Prarthana Jain, DO MPH
When we think of rheumatoid arthritis (RA), we often picture synovitis, autoantibodies, and joint destruction—hallmarks of chronic inflammation. A new era is emerging in which physicians can modulate inflammation not only through medications, but also through a small implant that adjusts neural signaling.
Why this matters
Despite major advances in biologics, a substantial number of patients continue to have inadequate disease control or experience adverse effects. Nearly half of RA patients discontinue DMARD therapy within three years—about 25% for lack of efficacy and 12% due to adverse events.1 This unmet need has driven exploration of novel, non-pharmacologic approaches, including neuromodulation.
The science behind vagus nerve stimulation
The vagus nerve (cranial nerve X) is a critical regulator of the “inflammatory reflex”—a neural circuit that dampens systemic cytokine release. Stimulation of the vagus nerve can decrease tumor necrosis factor (TNF), interleukin (IL)-1β, and IL-6 production through modulation of splenic and T-cell activity.2  In both animal and early human studies, vagus nerve stimulation (VNS) has demonstrated reduction in inflammatory cytokines and improvement in disease activity.
Clinical evidence and FDA approval
The RESET-RA trial was a randomized, double-blind, sham-controlled, multicenter, two-stage pivotal study evaluating the safety and efficacy of an implantable VNS device (the SetPoint System) in patients with moderate-to-severe RA who had inadequate responses or intolerance to biologic or targeted synthetic DMARDs.1
A total of 242 patients were enrolled across multiple international centers. The primary endpoint was achievement of an ACR 20% response (ACR20) at week 12. Results showed a statistically significant improvement in the active treatment group compared with controls—35.2% vs 24.2% (P = .0209; 95% CI, 0.6–23.1). Patients also demonstrated favorable trends in DAS28-CRP and other composite disease activity measures. 1
In July 2025, the U.S. Food and Drug Administration granted approval for the SetPoint System as adjunctive therapy in adults with moderate-to-severe RA who are intolerant of or have had inadequate responses to advanced therapies.3
The path forward
While VNS will likely not replace first-line DMARDs, it represents a transformative advance—a drug-sparing, biologic-free strategy that leverages the body’s own neural circuits to suppress inflammation. Questions remain regarding cost, access, long-term outcomes, and payer coverage, but the approval marks a significant step forward in the field of bioelectronic medicine.
Bottom line
For patients with difficult-to-treat RA, vagus nerve stimulation offers a novel therapeutic pathway grounded in neuro-immune modulation rather than traditional immunosuppression. As clinical experience expands, this technology may reshape how we think about inflammatory disease control in rheumatology.
References
- Kaplan J. Vagus Nerve Stimulation for Rheumatoid Arthritis: A New Approach to Reducing Inflammation. Rheumatology Advisor. Published March 14, 2024. Accessed October 26, 2025. https://www.rheumatologyadvisor.com/features/vagus-nerve-stimulation-for-rheumatoid-arthritis/
- Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016;113(29):8284-8289. doi:10.1073/pnas.1605635113
- SetPoint Medical. FDA Approves First Neuroimmune Modulation Therapy for Rheumatoid Arthritis. Press release. Published July 31, 2025. Accessed October 26, 2025. https://setpointmedical.com/setpoint-medical-receives-fda-approval-for-novel-neuroimmune-modulation-therapy-for-rheumatoid-arthritis/
- D’Haens GR, Tracey KJ. The inflammatory reflex and the role of the vagus nerve in immune regulation. Nat Rev Immunol. 2023;23(4):245-259. doi:10.1038/s41577-023-00857-2